Oncology Letters · 2017 · 14 citations · 27 references
MedicineOncologySurgeryOncologic SurgeryRhinologySurgical OncologyConcurrent ChemoradiationParanasal Sinus CancerSinonasal CancerSinonasal TumorsMalignant Sinonasal TumorsParanasal Sinus PathologyRadiation Therapy CombinationsRetrospective Case StudySinonasal NeoplasmsSinonasal Squamous Cell Carcinoma
Sinonasal carcinomas (SNcs) are rare neoplasms arising from the paranasal sinuses and nasal cavity. Although these tumours have a heterogeneous histology, they are commonly diagnosed as a locally advanced disease and are associated with a poor prognosis. The present retrospective study reviewed 30 patients with locally advanced SNc, who were treated with surgery followed by chemoradiotherapy or radiotherapy, or radiotherapy with or without concomitant chemotherapy between January 1999 and January 2013 at the Department of Radiation Therapy, University of Naples ‘Federico II’ (Naples, Italy). A total of 19 patients were treated with upfront surgery followed by adjuvant radio‑ or chemoradiotherapy (group A), while the remaining 11 patients received exclusive radiotherapy with or without concomitant chemotherapy (group B). Concurrent cisplatin‑based chemotherapy (100 mg/m2, days 1, 22 and 43 for 3 cycles) was administered to 34% of patients in group A and 55% of patients in group B. At a median follow‑up of 31 months, 33.3% of patients were alive. Cause‑specific survival (CSS) and progression‑free survival (PFS) times were 32 and 12 months, respectively. No difference in CSS rate was observed between the two treatment groups. Univariate analysis determined that disease stage was the only factor that significantly affected CSS (P=0.002) and PFS (P=0.0001) rates. Acute and chronic toxicities were mild, with only 23.3% of patients reporting G1‑2 side effects and no treatment‑related blindness. The present study reported moderate activity and efficacy of surgery followed by adjuvant radio‑ or chemoradiotherapy, and exclusive radiotherapy with or without chemotherapy in this poor prognosis category of patients.
27
James R. Egner · JAMA · 2010 · 6.1K citations
Barbara Burtness, Meredith A. Goldwasser, William A. Flood et al. · Journal of Clinical Oncology · 2005 · 883 citations
Medicine, Oncology, Pharmacology +17
Charlotte Jacobs, Gary H. Lyman, E Vélez-García et al. · Journal of Clinical Oncology · 1992 · 633 citations
Medicine, Oncology, Pharmacology +11
Head and Neck Cancers, Version 1.2015
David G. Pfister, Sharon A. Spencer, David M. Brizel et al. · Journal of the National Comprehensive Cancer Network · 2015 · 269 citations · Full text